In breast cancers, hormone receptor-positive luminal breast cancers exhibit variable glutamine dependency, whereas HER2-positive and triple-negative breast cancers appear to be highly dependent on exogenous glutamine and increased glutamine metabolism for survival [15,16,17]. Here, NR4A1 is linked to triple-negative breast carcinoma.